Active Ingredient History
Resiquimod (R-848) is a drug that acts as an immune response modifier, and has antiviral and antitumour activity. It is used as a topical gel in the treatment of skin lesions such as those caused by the herpes simplex virus and cutaneous T cell lymphoma, and as an adjuvant to increase the effectiveness of vaccines. In an animal disease model, systemic administration of resiquimod-loaded nanoparticles has been shown to improve response rates to cancer immunotherapy with a checkpoint inhibitor through stimulation of tumor-associated macrophages. It has several mechanisms of action, being both an agonist for toll-like receptor 7 and 8, and an upregulator of the opioid growth factor receptor. On 28 April 2016, orphan designation (EU/3/16/1653) was granted by the European Commission to Galderma R&D, France for resiquimod to be used in the treatment of cutaneous T-cell lymphoma. Wikipedia
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
Astrocytoma (Phase 2)
Carcinoma, Basal Cell (Phase 1/Phase 2)
Glioblastoma (Phase 2)
Glioma (Phase 2)
Hepatitis B (Phase 1/Phase 2)
Influenza Vaccines (Phase 1)
Keratosis, Actinic (Phase 2)
Lymphoma (Phase 1/Phase 2)
Lymphoma, T-Cell, Cutaneous (Phase 2)
Melanoma (Phase 2)
Neoplasms (Phase 1)
Oligodendroglioma (Phase 2)
Urinary Bladder Neoplasms (Phase 1/Phase 2)
Warts (Phase 2)
| Trial | Phase | Start Date | Organizations | Indications |
|---|
Feedback
Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).
Report issue